The Emerging Phenomenon of "Ozempic Feet": How Rapid Weight Loss with GLP-1 Drugs is Reshaping Podiatric Health
Podiatrists across major U.S. metropolises began observing a peculiar trend in late 2025. Patients, many of whom had recently commenced treatment with GLP-1 receptor agonist medications like Ozempic, Wegovy, Mounjaro, or Zepbound for weight management, were presenting with feet that appeared strikingly different from their previous visits. These changes were characterized by a noticeable bonier appearance, a sense of looseness, more prominent veins, and skin that seemed to no longer fit as snugly. Some patients described the sensation as akin to "walking on pebbles," while others reported a frustrating inability to find shoes that fit correctly. Curiously, these alterations were not detailed in the official medication labels.
This emerging condition, now colloquially termed "Ozempic feet," is gaining significant traction within podiatry circles and spreading across social media platforms. As the popularity of GLP-1 drugs for weight loss continues its upward trajectory, podiatrists nationwide are dedicating increased attention to this phenomenon. It’s crucial to understand that "Ozempic feet" isn’t a singular, dramatic complication. Instead, it represents a constellation of structural changes in the feet that arise from rapid fat loss. The feet, which rely on fat cushioning more than commonly realized, are bearing the brunt of these physiological shifts.
Understanding the mechanics behind this phenomenon requires a basic grasp of foot anatomy. Beneath the heel and the ball of the foot lie specialized fat pads – dense, compartmentalized cushions engineered to absorb the impact of every step. The plantar fat pad, specifically, is the layer of soft tissue situated between the skin and the heel bone, providing essential cushioning and support. For most of their lives, individuals utilize these pads without much thought, until they begin to diminish.
The Anatomical and Functional Impact of "Ozempic Feet"
The development of "Ozempic feet" signifies that rapid weight loss has accelerated the natural process of fat pad atrophy in the feet. While fat pad atrophy is a common consequence of aging, the potent effects of GLP-1 medications are compressing years of gradual change into a matter of months. When substantial weight is shed quickly, it can lead to a thinning of the plantar fat pad, resulting in heel pain, particularly during activities like walking or running.
The physical manifestations of this condition are far from subtle. Patients often notice their skin beginning to sag, with veins becoming more apparent on the tops and sides of their feet. However, these aesthetic changes are merely a surface-level indication of deeper structural issues. The plantar fat pads beneath the heel and the ball of the foot become thinner, significantly reducing their shock-absorbing capacity. This atrophy can render walking on hard surfaces painful and elevate the risk of developing pressure-related injuries.
This reduced padding can precipitate a range of problems, including the formation of corns and calluses, and general discomfort when walking barefoot on hard surfaces for extended periods. Dr. Dana Figura, a specialist in podiatric foot and ankle surgery, articulated the practical implications: "Some patients have gone down a full shoe size, and some have gone from a wide foot to a regular or narrow foot. These aren’t vanity complaints. They’re functional problems that can lead to blisters, calluses, ulcers and, in patients with diabetes, much more serious wounds."
The pain associated with fat pad thinning has a distinct pattern that warrants recognition. Fat pad atrophy typically manifests as a deep, cushion-less sensation directly under the heel bone. This is markedly different from plantar fasciitis, a far more commonly diagnosed heel condition, which usually presents as sharp pain closer to the arch, on the inner aspect of the heel. According to Physio-Pedia, heel fat pad syndrome is recognized as the second leading cause of plantar heel pain, accounting for 14.8% of cases, trailing only plantar fasciitis. Differentiating between these conditions is critical for effective treatment.
The Escalating Scale of the Problem
"Ozempic feet" is not officially listed among the most common side effects associated with Ozempic, Wegovy, or other GLP-1 medications. This official silence has left both patients and a significant number of clinicians unprepared for its emergence. Given the accelerating adoption of these drugs for weight loss, a pace that would have seemed improbable just five years ago, the disparity between documented side effects and observed clinical realities is rapidly widening.
As GLP-1 drugs continue to be a significant benefit for individuals seeking weight loss, this lesser-acknowledged side effect is commanding the attention of podiatrists across the nation. Gallup data from 2026 revealed that 11% of U.S. adults were using GLP-1 medications for weight loss, a substantial increase from just 3% in 2024. Further underscoring this trend, Truveta’s prescription tracking data indicated that as of March 2026, nearly 8 out of every 100 prescriptions in the U.S. were for GLP-1 receptor agonists. This represents the largest quarter-over-quarter increase recorded since 2019, with approximately 2.9 million patients prescribed a GLP-1 receptor agonist between January 2019 and March 2026.
Data presented at the American Diabetes Association’s 85th Scientific Sessions in 2025 highlighted a nearly 600% surge in the number of Americans utilizing incretin-based therapies, the drug class encompassing semaglutide, over the preceding five years. This exponential growth trajectory positions foot complications associated with these medications as a burgeoning public health issue, extending beyond the realm of niche podiatric concern.
Major podiatry practices in urban centers such as New York, Los Angeles, Chicago, Houston, Dallas, Atlanta, Miami, and Philadelphia have reported an increasing number of patient presentations consistent with "Ozempic feet." As of July 2026, a report by Medical Daily noted that no peer-reviewed studies had formally characterized "Ozempic feet" as a distinct clinical entity. The current evidentiary foundation relies on clinical observations, patient testimonials, and expert commentary – evidence that is undeniably real, consistent, and clinically significant, though not yet substantiated by randomized controlled trials.
The Biomechanical Basis: Why Fat Loss Disproportionately Affects the Feet
The specialized fat pads in the feet are not analogous to generic body fat. They are highly structured, compartmentalized tissues that have evolved specifically for impact absorption. When GLP-1 medications induce significant calorie restriction and subsequent weight loss, the body does not selectively preserve these specialized anatomical structures. Fat is mobilized from all storage sites, including the crucial cushioning layers beneath the heel and the ball of the foot.
When individuals carry excess weight for extended periods, their foot structure adapts to the sustained load. This adaptation can lead to flattening of the arches, stretching of the plantar fascia, and compression of the fat pads. Upon losing a significant amount of weight – say, 40, 60, or even 100 pounds – these structures do not instantaneously revert to their original form. Instead, they adjust gradually. During this period of adjustment, the foot’s biomechanics are fundamentally altered, leading to a mismatch with previously fitted footwear.
Muscle loss further exacerbates the problem. A systematic review and meta-analysis published in the journal Obesity in 2025 revealed that lean mass constituted approximately 30.8% of total body weight lost during GLP-1 therapy. This loss is particularly consequential for the feet, as the small intrinsic muscles within the feet play a vital role in supporting the arches and maintaining stability. As these muscles atrophy, foot mechanics are altered, potentially leading to different patterns of arch flattening and shifts in gait. Calf muscle mass reduction also impacts how the Achilles tendon is loaded and the overall stability of the ankle.
However, more recent research offers a degree of reassurance. A March 2026 study by Langer and colleagues, published in Cell Reports Medicine, found that weight loss induced by GLP-1 medications does not necessarily result in a disproportionate loss of muscle mass or function, provided that patients actively engage in resistance training. This caveat is critical: "when patients maintain resistance training." It suggests that individuals using GLP-1 medications who lead sedentary lifestyles may be at the highest risk for structural changes in their feet. Further insights into how GLP-1 medications affect the broader musculoskeletal system can be found in a previous Hearty Soul article discussing what orthopedic surgeons advise patients to know about Ozempic and their bones.
The skin’s capacity to adapt adds another layer to this complex issue. Dr. Claire Morrow, an orthopedic clinical specialist, observed that "if weight loss is too rapid, the skin doesn’t have time to adjust," leading to the loose, deflated appearance on the tops and sides of the feet that many patients find distressing. Individuals who lose more than 15% to 20% of their body weight within a year may be at an elevated risk for these types of changes.
Patients taking GLP-1 medications who have experienced a weight loss of 40 pounds or more, particularly those who lost weight rapidly over several months, are at increased risk. This risk is further amplified for individuals with pre-existing conditions that naturally thin fat pads, such as diabetes. Diabetes itself is associated with reduced plantar fat pad volume, and the additional fat loss induced by GLP-1 medications can exacerbate this. Furthermore, individuals who spend extended periods on their feet, including healthcare professionals, educators, retail workers, and restaurant staff, or anyone in a standing-dominant occupation, may experience pain earlier due to higher mechanical stress on their feet.
Individuals with diabetes face a compounded vulnerability. Those with type 2 diabetes already have an elevated risk of diabetic foot complications, including neuropathy and foot ulcers. According to the CDC, in 2024, 26.5% of adults with diagnosed diabetes were using GLP-1 injectables, with the highest usage observed in the 50 to 64 age group at 33.3%. When fat pad thinning is superimposed upon pre-existing neuropathy, even minor pressure injuries can escalate into serious wounds.
Sedentary patients who do not incorporate resistance training into their weight loss regimen are more susceptible to losing muscle mass and compromising fat pad integrity. Age is also a significant factor. Older adults naturally experience fat pad thinning as part of the aging process. Consequently, a patient in their 60s losing 50 pounds on a GLP-1 drug may experience the onset of genuinely painful foot changes much more rapidly than a younger individual losing the same amount of weight.
Addressing the Emerging Challenges of "Ozempic Feet"
The recommended course of action is not to discontinue medication. Instead, the focus should be on providing adequate cushioning, ensuring proper footwear, re-evaluating shoe fit, and seeking podiatric evaluation for persistent pain. The underlying weight loss achieved through these medications is, in the long term, demonstrably beneficial for foot health. The immediate challenge lies in effectively managing this transitional phase.
As fat pads thin, patients may experience new onset heel and forefoot pain even as they continue to lose weight. The use of high-cushioning footwear and metatarsal pads during the weight loss period can offer significant relief. Dr. Figura also advises patients to have their feet professionally measured again, to ensure they are wearing the correct shoe size, and to utilize extra cushioning, such as heel cups or inserts, if they perceive their fat pads to be thinner.
For more severe cases, over-the-counter orthotic insoles can partially compensate for reduced plantar fat pad volume. Custom orthotics, prescribed by a podiatrist, offer a more comprehensive and tailored solution.
In terms of prevention and management, protein intake and resistance training emerge as the two most actionable strategies. Maintaining muscle mass during weight loss is crucial for preserving the intrinsic foot muscles that support arch stability. The Mayo Clinic notes that patients taking GLP-1 medications often experience weight loss of 15% to 20% in clinical trials, which is more substantial than with most other weight-loss interventions. Consequently, strategies for muscle preservation are paramount throughout this process.
Implications for Patients and Healthcare Providers
Individuals currently taking GLP-1 medications who have experienced a weight loss of 30 pounds or more should pay close attention to the health of their feet. Warning signs to monitor include new onset heel pain during walking, a burning or aching sensation in the ball of the foot, footwear that suddenly feels too wide or too long, skin on the feet appearing looser or deflated, and more prominent tendons or veins that were not previously noticeable.
These symptoms do not necessitate stopping medication but do require proactive management. If pain is persistent, scheduling a podiatric evaluation is recommended. It is also advisable to have your feet re-measured before purchasing new footwear, as significant weight loss frequently alters shoe size and shape requirements. In the interim, wearing cushioned insoles or gel heel pads can provide immediate relief. For those not currently engaged in resistance training alongside their GLP-1 therapy, this presents a specific, evidence-based reason to commence such a program. Research from Langer et al. in 2026 clearly indicates that resistance exercise is the differentiating factor between patients who preserve functional muscle mass and those who do not – a distinction that is as evident in the feet as in any other part of the body.
The widespread adoption of GLP-1 medications for weight management, coupled with the emerging understanding of "Ozempic feet," highlights a critical need for increased awareness among both patients and healthcare providers. Podiatrists are at the forefront of identifying and managing these changes, but a broader dialogue is required to ensure that the full spectrum of potential side effects is understood and addressed proactively, safeguarding the long-term health and mobility of individuals undergoing these transformative treatments.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: What Really Happens to Your Body When You Quit Ozempic
